Novartis Sees Real Value Of Ofatumumab In MS, Pays GSK Up To $1Bn
This article was originally published in Scrip
GlaxoSmithKline is divesting its rights in ofatumumab in autoimmune indications, including multiple sclerosis, to Novartis. Novartis previously acquired the oncology rights for ofatumumab (marketed as Arzerra) as part of the major three-part transaction between the companies. It now holds complete rights to the fully human CD20-targeting monoclonal antibody.
You may also be interested in...
Novartis' Kesimpta Goes Up Against Roche's Ocrevus In MS
The anti-CD20 monoclonal antibody was approved by the US FDA for relapsing multiple sclerosis, bringing a new treatment to the crowded therapeutic area – with the benefit of self-administration.
Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?
A composition of matter patent for the Novartis MS drug Gilenya expires in 2019, but a recent inter partes review decision upheld a dosing patent that doesn't expire until 2027. However, analysts also touted the victory as a big win for Celgene and its competing S1P modulator ozanimod.
Novartis Withdraws Arzerra CLL Second-Line Use Filing in EU
Novartis has withdrawn its label extension application in Europe for use of Arzerra in combination with bendamustine for the treatment of relapsed chronic lymphocytic leukemia, following CHMP queries over a lack of comparable data.